van Meerten et al., Clin Cancer Res 2006
:
These findings suggest that CDC depends on CD20 expression level and that both CDC and ADCC act complementary
Verbrugge et al., Experimental hematology & oncology 2013
:
Here we studied the molecular basis of acquired resistance to BTZ in JY human B lymphoblastic cells following prolonged exposure to this drug and examined possibilities to overcome resistance by next generation PIs and anti-CD20/rituximab mediated complement dependent cytotoxicity ( CDC ) ... These results demonstrate that acquired resistance to BTZ in B cells can be overcome by next generation PIs and by anti-CD20/rituximab induced CDC , thereby paving the way for salvage therapy in BTZ-resistant disease